Totally agree and that was disappointing to say the least. Hell, look at how much and how many people ordered it from Rosetta in Bulgaria. Even if it was just ordering it online here in the US, revs would be pretty decent considering. Not sure why they were saying we would be in retail stores when we never had enough product here to begin with, and that's what they are supposedly addressing now. So yes the label change issue with the FDA, but the bigger issue was supply imo.
We have to remember though, this is a company of basically 4-6 people, and mistakes are going to be made and timelines are going to be missed. But what I don't see them doing is diluting and lining their pockets like most run OTC companies, in fact quite the opposite. I mean the whole reason to go public is to raise capital usually, so then being very frugal and going the partnership route to pay for the verticals we have now.
News 
Market Data 
Discover 
